Duchenne Families Sarepta Impact

News

Sarepta, Duchenne and gene therapy

For many Duchenne families, halt to gene therapy is heartbreak upon heartbreak

As gene therapy maker Sarepta Therapeutics tangles with FDA over its Duchenne treatment, patients and their families are caught in the middle.

BioPharma Dive · 1d

Sarepta woes mount as Duchenne gene therapy knocked back in Europe

· 8d · on MSN

Sarepta Refused FDA’s Request to Halt Elevidys Shipments

PharmExec3d

Recapping the Sarepta Saga—And Implications for Industry

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

Report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA ...

Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On

Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...

The Boston Globe1mon

Sarepta reports second patient death after treatment with Duchenne gene ...

Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for patients who can no longer walk, following the death of a second person who ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results